**Geoffrey M. Glass  
CEO, Kiniciti**

A person in a suit

Description automatically generated with medium confidence

**Geoffrey M. Glass** is currently CEO of Kiniciti, a Cell and Gene Therapy platform backed by Welsh, Carson, Anderson & Stowe. In addition to leading Kiniciti, Geoff is also Chairman of Avadel Pharmaceuticals (NASDAQ: AVDL).

Previously, Geoff was an Operating Partner at LongueVue Capital and CEO of Sancilio Pharmaceuticals, a specialty company in hematology and proprietary drug delivery.

In addition to serving on the board of Avadel, Geoff has served on the boards of directors for Sancilio Pharmaceuticals and Locus Biosciences.

Earlier in his career, Geoff spent nearly seven years as an executive with Patheon (now part of Thermo Fisher Scientific). He was the President of Banner Life Sciences, one of the stand-alone business units of Patheon. Banner developed, manufactured and commercialized prescription pharmaceuticals, OTC and nutritional products, for markets in the Americas and Europe. Prior to his role leading this business unit, Geoff was Executive Vice President of Sales and Marketing for Patheon Pharmaceuticals from 2009-2012. In each of these roles, Geoff was a member of the company’s executive committee.

Prior to joining Patheon in 2009, Geoff spent almost five years as a senior executive at Valeant Pharmaceuticals (now Bausch Health). Geoff was Senior Vice President, Asia Region at Valeant, and in this role had P&L responsibility for more than 250 prescription pharmaceuticals across 14 countries. Prior to his role in the Asian region, Geoff served Valeant as its Senior Vice President and CIO. In each of these roles Geoff was a member of the company’s executive committee.

Geoff began his career as a consultant in the Life Sciences practice for what was Ernst & Young and later became Cap Gemini.

Email: [partnering@kiniciti.com](mailto:partnering@kiniciti.com)